Developing a new family of antiepileptic drugs
Epilepsy is the most common serious chronic neurological condition and the most ubiquitous, affecting approximately 50 million people of all ages and social classes worldwide. Patients with epilepsy suffer from recurring seizures as a result of aberrant neuronal activity in the brain, and 30% are resistant to current therapies. Seizures may present in several ways, producing abnormal behaviour and perception, as well as loss of consciousness. Epileptic seizures become more common as people age. Although there are now various anticonvulsant drugs that reduce the number of seizures, there is no treatment to cure epilepsy or to prevent seizures.
Iproteos has developed a family of antiepileptic drugs that act directly on epileptogenesis, thus preventing the occurrence of seizures. The candidate drugs are now entering the preclinical proof-of-concept.
Since 2015, Iproteos has been participating in ECMED (Extracellular Matrix in Epileptogenesis), a project co-funded by the European Union’s Horizon 2020 Research and Innovation Programme. Lasting three years and with a budget of 3.5 million euros, ECMED aims to design innovative therapeutic strategies to further the development of a treatment and a diagnostic approach for the management of epilepsy.